News | May 16, 2025
Sanofi India posts 27% growth in operating profits in Q1 2025
Standalone profit from operations for the quarter were Rs. 162 crores
Standalone profit from operations for the quarter were Rs. 162 crores
The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
These observations are procedural in nature and none of them are related to data integrity
Investment demonstrates confidence in America’s commitment to science and innovation
The inspection concluded with 6 observations and none of them were related to Data Integrity
The closing of the Block Acquisition is now expected to be completed by Q3 2025
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
The transaction is expected to be completed by May 15, 2025 or such other date as may be mutually agreed
Subscribe To Our Newsletter & Stay Updated
